Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia
Schizophrenia is a devastating chronic psychotic disorder characterized by positive, negative, and cognitive symptoms. Although the positive symptoms are relatively well controlled by current monoamine-based treatments for schizophrenia, these agents provide only modest efficacy against the negative...
Saved in:
| Published in | Neuropharmacology Vol. 62; no. 3; pp. 1473 - 1483 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.03.2012
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Schizophrenia is a devastating chronic psychotic disorder characterized by positive, negative, and cognitive symptoms. Although the positive symptoms are relatively well controlled by current monoamine-based treatments for schizophrenia, these agents provide only modest efficacy against the negative and cognitive symptoms of the disease. Furthermore serious adverse events have been reported during treatment with antipsychotic drugs. Therefore, novel treatment strategies are needed that provide improved efficacy across the multiple symptom domains of schizophrenia and have improved tolerability/safety profiles. Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system (CNS) and plays an important role in physiological and pathological processes of the CNS. Group II metabotropic glutamate receptors (mGlu receptors), in particular, have been shown to modulate glutamatergic activity in brain synapses thought to be involved in the pathophysiology of schizophrenia. In recent years a number of selective mGlu2/3 receptor agonists and mGlu2 positive allosteric modulators have been disclosed with demonstrated efficacy in multiple animal models for schizophrenia. Consistent with predictions from pre-clinical animal studies, LY2140023 monohydrate, an mGlu2/3 receptor agonist prodrug, recently demonstrated evidence for antipsychotic activity in phase II proof of concept study. Although additional efficacy and safety studies are needed to understand the therapeutic potential of LY2140023, emerging preclinical and clinical data suggest that activation of group II mGlu receptors is a mechanistically novel and promising approach for the treatment of schizophrenia.
This article is part of a Special Issue entitled ‘Schizophrenia’.
► Schizophrenia is a devastating chronic psychotic disorder. ► Altered glutamate transmission is implicated in the pathophysiology schizophrenia. ► mGlu2/3 agonists and mGlu2 PAMs show efficacy in animal models of schizophrenia. ► LY2140023 demonstrated efficacy in a clinical trial for schizophrenia. ► Activation of mGlu2/3 is a mechanistically novel approach to treat schizophrenia. |
|---|---|
| AbstractList | Schizophrenia is a devastating chronic psychotic disorder characterized by positive, negative, and cognitive symptoms. Although the positive symptoms are relatively well controlled by current monoamine-based treatments for schizophrenia, these agents provide only modest efficacy against the negative and cognitive symptoms of the disease. Furthermore serious adverse events have been reported during treatment with antipsychotic drugs. Therefore, novel treatment strategies are needed that provide improved efficacy across the multiple symptom domains of schizophrenia and have improved tolerability/safety profiles. Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system (CNS) and plays an important role in physiological and pathological processes of the CNS. Group II metabotropic glutamate receptors (mGlu receptors), in particular, have been shown to modulate glutamatergic activity in brain synapses thought to be involved in the pathophysiology of schizophrenia. In recent years a number of selective mGlu2/3 receptor agonists and mGlu2 positive allosteric modulators have been disclosed with demonstrated efficacy in multiple animal models for schizophrenia. Consistent with predictions from pre-clinical animal studies, LY2140023 monohydrate, an mGlu2/3 receptor agonist prodrug, recently demonstrated evidence for antipsychotic activity in phase II proof of concept study. Although additional efficacy and safety studies are needed to understand the therapeutic potential of LY2140023, emerging preclinical and clinical data suggest that activation of group II mGlu receptors is a mechanistically novel and promising approach for the treatment of schizophrenia.Schizophrenia is a devastating chronic psychotic disorder characterized by positive, negative, and cognitive symptoms. Although the positive symptoms are relatively well controlled by current monoamine-based treatments for schizophrenia, these agents provide only modest efficacy against the negative and cognitive symptoms of the disease. Furthermore serious adverse events have been reported during treatment with antipsychotic drugs. Therefore, novel treatment strategies are needed that provide improved efficacy across the multiple symptom domains of schizophrenia and have improved tolerability/safety profiles. Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system (CNS) and plays an important role in physiological and pathological processes of the CNS. Group II metabotropic glutamate receptors (mGlu receptors), in particular, have been shown to modulate glutamatergic activity in brain synapses thought to be involved in the pathophysiology of schizophrenia. In recent years a number of selective mGlu2/3 receptor agonists and mGlu2 positive allosteric modulators have been disclosed with demonstrated efficacy in multiple animal models for schizophrenia. Consistent with predictions from pre-clinical animal studies, LY2140023 monohydrate, an mGlu2/3 receptor agonist prodrug, recently demonstrated evidence for antipsychotic activity in phase II proof of concept study. Although additional efficacy and safety studies are needed to understand the therapeutic potential of LY2140023, emerging preclinical and clinical data suggest that activation of group II mGlu receptors is a mechanistically novel and promising approach for the treatment of schizophrenia. Schizophrenia is a devastating chronic psychotic disorder characterized by positive, negative, and cognitive symptoms. Although the positive symptoms are relatively well controlled by current monoamine-based treatments for schizophrenia, these agents provide only modest efficacy against the negative and cognitive symptoms of the disease. Furthermore serious adverse events have been reported during treatment with antipsychotic drugs. Therefore, novel treatment strategies are needed that provide improved efficacy across the multiple symptom domains of schizophrenia and have improved tolerability/safety profiles. Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system (CNS) and plays an important role in physiological and pathological processes of the CNS. Group II metabotropic glutamate receptors (mGlu receptors), in particular, have been shown to modulate glutamatergic activity in brain synapses thought to be involved in the pathophysiology of schizophrenia. In recent years a number of selective mGlu2/3 receptor agonists and mGlu2 positive allosteric modulators have been disclosed with demonstrated efficacy in multiple animal models for schizophrenia. Consistent with predictions from pre-clinical animal studies, LY2140023 monohydrate, an mGlu2/3 receptor agonist prodrug, recently demonstrated evidence for antipsychotic activity in phase II proof of concept study. Although additional efficacy and safety studies are needed to understand the therapeutic potential of LY2140023, emerging preclinical and clinical data suggest that activation of group II mGlu receptors is a mechanistically novel and promising approach for the treatment of schizophrenia. Schizophrenia is a devastating chronic psychotic disorder characterized by positive, negative, and cognitive symptoms. Although the positive symptoms are relatively well controlled by current monoamine-based treatments for schizophrenia, these agents provide only modest efficacy against the negative and cognitive symptoms of the disease. Furthermore serious adverse events have been reported during treatment with antipsychotic drugs. Therefore, novel treatment strategies are needed that provide improved efficacy across the multiple symptom domains of schizophrenia and have improved tolerability/safety profiles. Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system (CNS) and plays an important role in physiological and pathological processes of the CNS. Group II metabotropic glutamate receptors (mGlu receptors), in particular, have been shown to modulate glutamatergic activity in brain synapses thought to be involved in the pathophysiology of schizophrenia. In recent years a number of selective mGlu2/3 receptor agonists and mGlu2 positive allosteric modulators have been disclosed with demonstrated efficacy in multiple animal models for schizophrenia. Consistent with predictions from pre-clinical animal studies, LY2140023 monohydrate, an mGlu2/3 receptor agonist prodrug, recently demonstrated evidence for antipsychotic activity in phase II proof of concept study. Although additional efficacy and safety studies are needed to understand the therapeutic potential of LY2140023, emerging preclinical and clinical data suggest that activation of group II mGlu receptors is a mechanistically novel and promising approach for the treatment of schizophrenia. This article is part of a Special Issue entitled ‘Schizophrenia’. ► Schizophrenia is a devastating chronic psychotic disorder. ► Altered glutamate transmission is implicated in the pathophysiology schizophrenia. ► mGlu2/3 agonists and mGlu2 PAMs show efficacy in animal models of schizophrenia. ► LY2140023 demonstrated efficacy in a clinical trial for schizophrenia. ► Activation of mGlu2/3 is a mechanistically novel approach to treat schizophrenia. |
| Author | Fell, Matthew J. McKinzie, David L. Svensson, Kjell A. Monn, James A. |
| Author_xml | – sequence: 1 givenname: Matthew J. surname: Fell fullname: Fell, Matthew J. – sequence: 2 givenname: David L. surname: McKinzie fullname: McKinzie, David L. – sequence: 3 givenname: James A. surname: Monn fullname: Monn, James A. – sequence: 4 givenname: Kjell A. surname: Svensson fullname: Svensson, Kjell A. email: Svensson_Kjell_A@lilly.com |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21704048$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU1r3DAQhkVIaTZp_0LQrSc7kr8kXwptaNOFQC_tWcij2USLLLmSvND8-ihsQiGX9CQGnvcZMe85OfXBIyGUs5ozPlzta49rDMu9jnPdMM5rNtSMiROy4VK0lWBDd0o2jDWyakcmz8h5SnvGWCe5fE_OGi5YV4YNebiJYV3odktnzHoKuVgt0Du3Zj3rjDQi4JJDpPoueJtyotobuoRksz0g1c6FlDGWzBzM6nRBC5KoDwd0NEfUeUZfYrviSHBvH8q3I3qrP5B3O-0Sfnx-L8jv799-Xf-obn_ebK-_3FbQCZ4r00PLO9Cin6aeix44F-3OGBjM2As9Aspp6obejAwMAvSyA-SmwakZceTYXpBPR-8Sw58VU1azTYDOaY9hTWpsWl5Mg3ybLOvF0PCmkJfP5DrNaNQS7azjX_Vy2AJ8PgIQQ0oRdwps1tkGn6O2TnGmnppUe_WvSfXUpGKDKk0WgXwleNnxH9GvxyiWqx4sRpXAogc0trSZlQn2bckjjdjDew |
| CitedBy_id | crossref_primary_10_5402_2012_427267 crossref_primary_10_1021_acs_jmedchem_5b01333 crossref_primary_10_1517_13543776_2014_983899 crossref_primary_10_1177_0269881115573403 crossref_primary_10_1097_YCO_0b013e32835dd9de crossref_primary_10_3389_fnins_2021_641047 crossref_primary_10_1016_j_neuropharm_2016_06_020 crossref_primary_10_1016_j_neuropharm_2014_03_018 crossref_primary_10_1002_syn_21734 crossref_primary_10_1016_j_neuropharm_2012_11_015 crossref_primary_10_1016_j_neuropharm_2012_05_026 crossref_primary_10_1016_j_schres_2016_04_015 crossref_primary_10_1007_s10787_017_0340_5 crossref_primary_10_1016_j_neuropharm_2012_05_023 crossref_primary_10_1517_13543776_2013_777043 crossref_primary_10_1124_jpet_113_204990 crossref_primary_10_1038_s41398_023_02455_w crossref_primary_10_1155_2014_307106 crossref_primary_10_3389_fpsyt_2018_00544 crossref_primary_10_1111_bcp_14331 crossref_primary_10_3390_ijms21228811 crossref_primary_10_1016_j_str_2017_05_021 crossref_primary_10_1038_s41380_018_0069_6 crossref_primary_10_1016_j_neuropharm_2017_09_014 crossref_primary_10_1016_j_nlm_2017_02_004 crossref_primary_10_1021_jm3010724 crossref_primary_10_1039_D1CP02157E crossref_primary_10_1016_j_expneurol_2015_08_019 crossref_primary_10_1016_j_neulet_2013_12_016 crossref_primary_10_1016_j_neuropharm_2020_108231 crossref_primary_10_1177_0269881114565806 crossref_primary_10_3389_fphar_2014_00177 crossref_primary_10_3389_fpsyt_2019_00049 crossref_primary_10_1021_jm4000165 crossref_primary_10_1038_npp_2013_4 crossref_primary_10_1080_13543776_2019_1637421 crossref_primary_10_1016_j_neuropharm_2015_11_031 crossref_primary_10_1016_j_neuropharm_2014_07_009 crossref_primary_10_1371_journal_pone_0061787 crossref_primary_10_1002_brb3_2466 crossref_primary_10_1016_j_bcp_2012_04_013 crossref_primary_10_1016_j_phrs_2016_11_029 crossref_primary_10_3389_fphar_2023_1111915 crossref_primary_10_1016_j_neuropharm_2019_05_009 crossref_primary_10_1007_s40265_017_0789_y crossref_primary_10_1021_acs_chemrev_5b00656 crossref_primary_10_1016_j_neuropharm_2016_04_044 crossref_primary_10_1007_s10787_017_0366_8 crossref_primary_10_3390_ijms18010135 crossref_primary_10_1016_j_neuroscience_2013_07_010 crossref_primary_10_1016_j_pnpbp_2015_02_015 crossref_primary_10_1097_FBP_0000000000000183 crossref_primary_10_1124_jpet_114_218651 crossref_primary_10_1016_j_neuint_2015_03_010 crossref_primary_10_1007_s10787_018_0455_3 crossref_primary_10_1007_s13760_014_0407_7 crossref_primary_10_1016_j_pnpbp_2015_02_012 crossref_primary_10_1016_j_neulet_2013_08_073 crossref_primary_10_1002_syn_21689 crossref_primary_10_1016_j_niox_2024_11_010 crossref_primary_10_1016_j_nbd_2020_104807 crossref_primary_10_1016_j_bbr_2014_03_008 crossref_primary_10_3389_fphar_2016_00130 crossref_primary_10_1111_bph_13850 crossref_primary_10_1016_j_brainres_2018_03_007 crossref_primary_10_1016_j_ejmech_2020_112521 crossref_primary_10_1155_2015_716514 crossref_primary_10_1155_2022_8425640 crossref_primary_10_4155_fmc_13_118 crossref_primary_10_3109_15622975_2012_696143 |
| Cites_doi | 10.1016/S0306-4522(02)00652-8 10.1016/j.brainres.2007.12.057 10.1046/j.1460-9568.2003.02657.x 10.1097/01.ypg.0000056682.82896.b0 10.1016/S0893-133X(99)00132-3 10.1016/S0022-3565(24)29296-X 10.1016/S0014-2999(99)00844-4 10.1056/NEJMra035458 10.1016/S0893-133X(00)00136-6 10.1124/jpet.109.160598 10.1124/jpet.108.138271 10.1016/j.neubiorev.2010.01.002 10.1152/jn.00875.2004 10.1093/schbul/19.2.199 10.1124/mol.64.4.798 10.1016/j.biopsych.2006.12.005 10.1016/0028-3908(90)90034-O 10.1016/S0166-2236(96)20019-0 10.1146/annurev.pharmtox.42.082701.160735 10.1016/j.ejphar.2010.02.058 10.1021/jm9601765 10.1001/archpsyc.1995.03950240016004 10.1196/annals.1300.019 10.1016/0306-4522(93)90485-X 10.1046/j.1471-4159.2000.0751147.x 10.1176/ajp.156.11.1686 10.1021/ml100115a 10.1124/jpet.106.102046 10.1096/fj.10-163147 10.1007/s00213-004-2127-9 10.1007/s00213-010-1914-8 10.1016/j.neuropharm.2009.11.014 10.1038/nature06612 10.1038/sj.npp.1300238 10.1007/s00213-003-1444-8 10.1517/13543770903045009 10.1016/S0014-2999(00)00269-7 10.1016/j.schres.2010.02.037 10.1007/s00213-004-1982-8 10.1016/j.neuroscience.2010.02.057 10.1016/j.schres.2007.11.007 10.1016/j.schres.2005.04.001 10.1124/jpet.105.091074 10.1016/j.schres.2009.03.038 10.1093/cercor/bhi087 10.1016/S0022-3565(25)38596-4 10.1016/0091-3057(94)90506-1 10.1002/syn.20704 10.1002/cne.903350209 10.1146/annurev.pharmtox.011008.145533 10.1007/s002130000590 10.1016/j.tins.2008.02.005 10.1016/j.schres.2004.07.002 10.1016/S0014-2999(96)00956-9 10.1523/JNEUROSCI.1889-07.2007 10.1007/s10571-006-9062-8 10.1124/jpet.108.136861 10.1007/s00213-009-1644-y 10.1016/S0028-3908(99)00092-1 10.1016/0304-3940(80)90178-0 10.1016/j.schres.2010.02.679 10.1016/S0014-2999(00)00423-4 10.1016/0028-3908(88)90189-X 10.1038/sj.mp.4001556 10.1016/S0022-3956(99)00029-1 10.1007/s00213-007-0974-x 10.1038/sj.npp.1301531 10.1016/0306-4522(95)00533-1 10.1021/jm980616n 10.1038/sj.npp.1300013 10.1001/archpsyc.1994.03950030035004 10.1016/S0006-8993(97)01390-5 10.1523/JNEUROSCI.4623-10.2010 10.1002/syn.20164 10.1021/jm060917u 10.1111/j.1527-3458.2007.00024.x 10.1007/s00213-004-2099-9 10.1146/annurev.pharmtox.37.1.205 10.1038/nm1632 10.1523/JNEUROSCI.15-05-03896.1995 10.1016/S0028-3908(97)00051-8 10.1038/sj.mp.4001751 10.1002/syn.20482 10.1016/j.bmcl.2010.03.089 10.1016/S0091-3057(02)00845-6 10.1016/S0006-3223(99)00153-5 10.1038/nm0907-1018 10.1016/S0022-3565(24)35262-0 10.1021/jm000346k 10.1016/0893-133X(94)00129-N 10.1124/jpet.110.170506 10.1016/j.neuropharm.2004.01.018 10.1021/jm9606756 10.1097/00001756-200109170-00043 10.1073/pnas.0405077101 10.1038/sj.npp.1301547 10.1016/j.neuropharm.2004.12.022 10.1007/s00213-007-0758-3 10.1016/S0006-8993(99)01776-X 10.1124/jpet.106.110809 10.1126/science.281.5381.1349 10.1007/s00213-004-2126-x 10.1016/S0028-3908(01)00034-X 10.1523/JNEUROSCI.22-21-09150.2002 10.1007/s00213-010-2052-z 10.1016/0163-7258(93)90036-D 10.1016/S0022-3565(24)35084-0 10.1007/s00213-007-0742-y 10.1097/FBP.0b013e3283242f57 10.2174/1568007023339544 10.1016/S0924-977X(03)92148-1 10.1038/sj.npp.1395318 10.1007/s002130050072 10.1097/00004647-200109000-00001 10.1038/nm1418 10.1176/appi.ajp.157.7.1141 10.1124/mol.107.035170 10.1038/sj.npp.1300824 10.1176/ajp.148.10.1301 10.1523/JNEUROSCI.16-01-00019.1996 10.1046/j.1471-4159.2000.0750889.x 10.1016/S0022-3565(24)29402-7 10.1523/JNEUROSCI.17-08-02921.1997 |
| ContentType | Journal Article |
| Copyright | 2011 Elsevier Ltd Copyright © 2011 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2011 Elsevier Ltd – notice: Copyright © 2011 Elsevier Ltd. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TK |
| DOI | 10.1016/j.neuropharm.2011.06.007 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Neurosciences Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Neurosciences Abstracts |
| DatabaseTitleList | MEDLINE - Academic Neurosciences Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-7064 |
| EndPage | 1483 |
| ExternalDocumentID | 21704048 10_1016_j_neuropharm_2011_06_007 S0028390811002437 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M -~X .55 .GJ .~1 0R~ 123 1B1 1RT 1~. 1~5 29N 3O- 4.4 41~ 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AADPK AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXLA AAXUO ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADIYS ADMUD AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMQ HMT HVGLF HZ~ IHE J1W K-O KOM L7B M2V M34 M41 MO0 MOBAO N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SNS SPCBC SPT SSN SSP SSZ T5K TEORI WUQ X7M XOL ZGI ZXP ~G- AATTM AAXKI AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION EFKBS CGR CUY CVF ECM EIF NPM SSH 7X8 7TK |
| ID | FETCH-LOGICAL-c471t-d5c314ca75bb5175c1173fddc6d957a9ce8bb465d90cdecc584ce1d2eb29e91e3 |
| IEDL.DBID | .~1 |
| ISSN | 0028-3908 1873-7064 |
| IngestDate | Thu Jul 10 18:14:26 EDT 2025 Fri Jul 11 02:32:32 EDT 2025 Thu Apr 03 07:07:47 EDT 2025 Tue Aug 05 12:07:14 EDT 2025 Thu Apr 24 23:00:17 EDT 2025 Fri Feb 23 02:30:52 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | LY379268 LY354740 LY487379 5HT (−)-DOB mGlu2/3 receptor agonist LY2140023 Schizophrenia mGlu2 positive allosteric modulator NMDA PANSS 5HT2A DOI LY544344 BINA Glutamate THIIC mGlu mPFC LY341495 CBiPES LY404039 NE PCP DA PAM |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2011 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c471t-d5c314ca75bb5175c1173fddc6d957a9ce8bb465d90cdecc584ce1d2eb29e91e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 21704048 |
| PQID | 917576212 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_923195768 proquest_miscellaneous_917576212 pubmed_primary_21704048 crossref_citationtrail_10_1016_j_neuropharm_2011_06_007 crossref_primary_10_1016_j_neuropharm_2011_06_007 elsevier_sciencedirect_doi_10_1016_j_neuropharm_2011_06_007 |
| PublicationCentury | 2000 |
| PublicationDate | March 2012 2012-03-00 2012-Mar 20120301 |
| PublicationDateYYYYMMDD | 2012-03-01 |
| PublicationDate_xml | – month: 03 year: 2012 text: March 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Neuropharmacology |
| PublicationTitleAlternate | Neuropharmacology |
| PublicationYear | 2012 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Zhai, George, Zhai, Nisenbaum, Johnson, Nisenbaum (bib127) 2003; 28 Garbaccio, Brnardic, Fraley, Hartman, Hutson, O’Brien, Magliaro, Uslaner, Huszar, Fillgrove, Small, Tang, Kuo, Jacobson (bib46) 2010; 1 Freedman (bib41) 2003; 349 Tsai, Coyle (bib121) 2002; 42 Chen, He, Wu, Xu, Feng, Li, Wang, He (bib22) 2005; 73 Roth, Craigo, Choudhary, Uluer, Monsma, Shen, Meltzer, Sibley (bib106) 1994; 268 Aultman, Moghaddam (bib8) 2001; 153 Pehrson, Moghaddam (bib101) 2010; 211 Cartmell, Monn, Schoepp (bib17) 2000; 148 Petralia, Wang, Niedzielski, Wenthold (bib102) 1996; 71 Hahn, Wang, Cho, Talbot, Gur, Berrettini, Bakshi, Kamins, Borgmann-Winter, Siegel, Gallop, Arnold (bib57) 2006; 12 Rorick-Kehn, Johnson, Knitowski, Salhoff, Witkin, Perry, Griffey, Tizzano, Monn, McKinzie, Schoepp (bib105) 2007; 193 Taber, Fibiger (bib120) 1995; 15 Coyle (bib27) 2006; 26 Bromet, Fennig (bib13) 1999; 46 Parada-Turska, Turski (bib99) 1990; 29 Doumazane, Scholler, Zwier, Trinquet, Rondard, Pin (bib31) 2011 Lorrain, Baccei, Correa, Bristow (bib77) 2005; 48 Schreiber, Lowe, Voerste, De Vry (bib112) 2000; 388 Monn, Valli, Massey, Hansen, Kress, Wepsiec, Harkness, Grutsch, Wright, Johnson, Andis, Kingston, Tomlinson, Lewis, Griffey, Tizzano, Schoepp (bib89) 1999; 42 Cherlyn, Woon, Liu, Ong, Tsai, Sim (bib23) 2010; 34 Gao, Sakai, Roberts, Conley, Dean, Tamminga (bib45) 2000; 157 Moghaddam, Adams, Verma, Daly (bib85) 1997; 17 Benneyworth, Xiang, Smith, Garcia, Conn, Sanders-Bush (bib9) 2007; 72 Rorick-Kehn, Johnson, Burkey, Wright, Calligaro, Marek, Nisenbaum, Catlow, Kingston, Giera, Herin, Monn, McKinzie, Schoepp (bib104) 2007; 321 Law, Deakin (bib74) 2001; 12 Krystal, Belger, D’Souza, Anand, Charney, Aghajanian, Moghaddam (bib71) 1999; 22 Monn, Valli, Johnson, Salhoff, Wright, Howe, Bond, Lodge, Spangle, Paschal, Campbell, Griffey, Tizzano, Schoepp (bib88) 1996; 39 Ellenbroek (bib36) 1993; 57 Homayoun, Jackson, Moghaddam (bib61) 2005; 93 Zysk, Widzowski, Sygowski, Knappenberger, Spear, Elmore, Dorff, Liu, Doherty, Chhajlani (bib128) 2010 Lahti, Holcomb, Gao, Tamminga (bib73) 1999; 22 Danysz, Wroblewski, Costa (bib29) 1988; 27 Auclair, Cotecchia, Glowinski, Tassin (bib7) 2002; 22 Galici, Echemendia, Rodriguez, Conn (bib43) 2005; 315 Jones, Brown, Auer, Fone (bib66) 2010 Spooren, Gasparini, van der Putten, Koller, Nakanishi, Kuhn (bib117) 2000; 397 Ghose, Chin, Gallegos, Roberts, Coyle, Tamminga (bib48) 2009; 111 Miyamoto, Duncan, Marx, Lieberman (bib84) 2005; 10 Greco, Invernizzi, Carli (bib51) 2005; 179 Seeman, Caruso, Lasaga (bib114) 2008; 62 Andreasen, Carpenter (bib5) 1993; 19 Schaffhauser, Rowe, Morales, Chavez-Noriega, Yin, Jachec, Rao, Bain, Pinkerton, Vernier, Bristow, Varney, Daggett (bib108) 2003; 64 Schlumberger, Schafer, Barberi, More, Nagel, Pietraszek, Schmidt, Danysz (bib109) 2009; 20 Gozzi, Large, Schwarz, Bertani, Crestan, Bifone (bib50) 2008; 33 Marek (bib79) 2010; 639 Aghajanian, Marek (bib1) 1997; 36 Schoepp, Jane, Monn (bib111) 1999; 38 Krystal, Abi-Saab, Perry, D’Souza, Liu, Gueorguieva, McDougall, Hunsberger, Belger, Levine, Breier (bib70) 2005; 179 Akbarian, Sucher, Bradley, Tafazzoli, Trinh, Hetrick, Potkin, Sandman, Bunney, Jones (bib3) 1996; 16 Bruno, Battaglia, Copani, D’Onofrio, Di Iorio, De Blasi, Melchiorri, Flor, Nicoletti (bib14) 2001; 21 Nicoletti, Bruno, Copani, Casabona, Knopfel (bib92) 1996; 19 Boyle, Trick, Soo-ampon, Lilley, Levine, Hindmarch (bib11) 2003; 13 Marino, Conn (bib82) 2002; 1 Schoepp (bib110) 2001; 299 Wright, Arnold, Wheeler, Ornstein, Schoepp (bib125) 2001; 298 Ohishi, Shigemoto, Nakanishi, Mizuno (bib95) 1993; 53 Lorrain, Schaffhauser, Campbell, Baccei, Correa, Rowe, Rodriguez, Anderson, Varney, Pinkerton, Vernier, Bristow (bib78) 2003; 28 Galici, Jones, Hemstapat, Nong, Echemendia, Williams, de Paulis, Conn (bib44) 2006; 318 Patil, Zhang, Martenyi, Lowe, Jackson, Andreev, Avedisova, Bardenstein, Gurovich, Morozova, Mosolov, Neznanov, Reznik, Smulevich, Tochilov, Johnson, Monn, Schoepp (bib100) 2007; 13 Niswender, Conn (bib94) 2010; 50 Homayoun, Moghaddam (bib62) 2006; 16 Cartmell, Monn, Schoepp (bib16) 1999; 291 Imre (bib63) 2007; 13 Gewirtz, Marek (bib47) 2000; 23 Pilowsky, Bressan, Stone, Erlandsson, Mulligan, Krystal, Ell (bib103) 2006; 11 Woolley, Pemberton, Bate, Corti, Jones (bib124) 2008; 196 Conn, Pin (bib24) 1997; 37 Fell, Perry, Falcone, Johnson, Barth, Rash, Lucaites, Threlkeld, Monn, McKinzie, Marek, Svensson, Nelson (bib39) 2009; 331 Ohishi, Shigemoto, Nakanishi, Mizuno (bib96) 1993; 335 Spinelli, Ballard, Gatti-McArthur, Richards, Kapps, Woltering, Wichmann, Stadler, Feldon, Pryce (bib116) 2005; 179 Uslaner, Smith, Huszar, Pachmerhiwala, Hinchliffe, Vardigan, Hutson (bib122) 2009; 206 Swanson, Schoepp (bib119) 2003; 1003 Grillon, Cordova, Levine, Morgan (bib52) 2003; 168 Fell, Katner, Johnson, Khilevich, Schkeryantz, Perry, Svensson (bib38) 2010; 58 Weinberger (bib123) 2007; 13 Dedeurwaerdere, Wintmolders, Straetemans, Pemberton, Langlois (bib30) 2010; 214 Marek, Wright, Johnson, Svensson, Benvenga, Chaney, Schoepp, Monn (bib80) 2008; 55 Olney, Newcomer, Farber (bib98) 1999; 33 Cartmell, Monn, Schoepp (bib18) 2000; 400 Zeng, Le, Richelson (bib126) 1997; 321 Svensson (bib118) 2010; 117 Aronica, Gorter, Ijlst-Keizers, Rozemuller, Yankaya, Leenstra, Troost (bib6) 2003; 17 Johnson, Barda, Britton, Emkey, Hornback, Jagdmann, McKinzie, Nisenbaum, Tizzano, Schoepp (bib65) 2005; 179 Lorrain, Baccei, Bristow, Anderson, Varney (bib76) 2003; 117 Lisman, Coyle, Green, Javitt, Benes, Heckers, Grace (bib75) 2008; 31 Rowe, Schaffhauser, Morales, Lubbers, Bonnefous, Kamenecka, McQuiston, Daggett (bib107) 2008; 326 Cartmell, Perry, Salhoff, Monn, Schoepp (bib20) 2001; 40 Olney, Farber (bib97) 1995; 52 Dunayevich, Erickson, Levine, Landbloom, Schoepp, Tollefson (bib32) 2008; 33 Aghajanian, Marek (bib2) 1999; 21 Seeman, Guan (bib115) 2009; 63 Egan, Straub, Goldberg, Yakub, Callicott, Hariri, Mattay, Bertolino, Hyde, Shannon-Weickert, Akil, Crook, Vakkalanka, Balkissoon, Gibbs, Kleinman, Weinberger (bib35) 2004; 101 Kinon, Zhang, Williams, Osuntokun, Millen, Kollack-Walker (bib68) 2010; 117 Monn, Massey, Valli, Henry, Stephenson, Bures, Herin, Catlow, Giera, Wright, Johnson, Andis, Kingston, Schoepp (bib87) 2007; 50 Higgins, Ballard, Kew, Richards, Kemp, Adam, Woltering, Nakanishi, Mutel (bib59) 2004; 46 Cartmell, Schoepp (bib21) 2000; 75 Gonzalez-Maeso, Ang, Yuen, Chan, Weisstaub, Lopez-Gimenez, Zhou, Okawa, Callado, Milligan, Gingrich, Filizola, Meana, Sealfon (bib49) 2008; 452 Holcomb, Lahti, Medoff, Cullen, Tamminga (bib60) 2005; 30 Marek, Wright, Schoepp, Monn, Aghajanian (bib81) 2000; 292 Moghaddam, Adams (bib86) 1998; 281 Krystal, Karper, Seibyl, Freeman, Delaney, Bremner, Heninger, Bowers, Charney (bib72) 1994; 51 Allison, Mentore, Heo, Chandler, Cappelleri, Infante, Weiden (bib4) 1999; 156 Javitt, Zukin (bib64) 1991; 148 Duncan, Moy, Knapp, Mueller, Breese (bib34) 1998; 787 Gupta, McCullumsmith, Beneyto, Haroutunian, Davis, Meador-Woodruff (bib55) 2005; 57 Cartmell, Perry, Salhoff, Monn, Schoepp (bib19) 2000; 75 Corti, Battaglia, Molinaro, Riozzi, Pittaluga, Corsi, Mugnaini, Nicoletti, Bruno (bib25) 2007; 27 Klodzinska, Bijak, Tokarski, Pilc (bib69) 2002; 73 Duncan, Miyamoto, Leipzig, Lieberman (bib33) 1999; 843 Brnardic, Fraley, Garbaccio, Layton, Sanders, Culberson, Jacobson, Magliaro, Hutson, O’Brien, Huszar, Uslaner, Fillgrove, Tang, Kuo, Sur, Hartman (bib12) 2010; 20 Michelson, Levine, Mesters, Schoepp, Dunayevich, Tollefson (bib83) 2005; 49 Kim, Kornhuber, Schmid-Burgk, Holzmuller (bib67) 1980; 20 Gruber, Calhoon, Shusterman, Schoenbaum, Roesch, O’Donnell (bib53) 2010; 30 Hackler, Byun, Jones, Williams, Baheza, Sengupta, Grier, Avison, Conn, Gore (bib56) 2010; 168 Corti, Crepaldi, Mion, Roth, Xuereb, Ferraguti (bib26) 2007; 62 Fraley (bib40) 2009; 19 Harich, Gross, Bespalov (bib58) 2007; 192 Fujii, Shibata, Kikuta, Makino, Tani, Hirata, Shibata, Ninomiya, Tashiro, Fukumaki (bib42) 2003; 13 Monn, Valli, Massey, Wright, Salhoff, Johnson, Howe, Alt, Rhodes, Robey, Griffey, Tizzano, Kallman, Helton, Schoepp (bib90) 1997; 40 Danysz, Essmann, Bresink, Wilke (bib28) 1994; 48 Bymaster, Calligaro, Falcone, Marsh, Moore, Tye, Seeman, Wong (bib15) 1996; 14 Gu, Lorrain, Wei, Cole, Zhang, Daggett, Schaffhauser, Bristow, Lechner (bib54) 2008; 1197 Nikiforuk, Popik, Drescher, van Gaalen, Relo, Mezler, Marek, Schoemaker, Gross, Bespalov (bib93) 2010 Nakazato, Kumagai, Sakagami, Yoshikawa, Suzuki, Chaki, Ito, Taguchi, Nakanishi, Okuyama (bib91) 2000; 43 Bishop, Ellingrod, Moline, Miller (bib10) 2005; 77 Fell, Johnson, Svensson, Schoepp (bib37) 2008; 326 Seeman (bib113) 2008; 99 Fell (10.1016/j.neuropharm.2011.06.007_bib38) 2010; 58 Gewirtz (10.1016/j.neuropharm.2011.06.007_bib47) 2000; 23 Lorrain (10.1016/j.neuropharm.2011.06.007_bib78) 2003; 28 Taber (10.1016/j.neuropharm.2011.06.007_bib120) 1995; 15 Conn (10.1016/j.neuropharm.2011.06.007_bib24) 1997; 37 Ellenbroek (10.1016/j.neuropharm.2011.06.007_bib36) 1993; 57 Olney (10.1016/j.neuropharm.2011.06.007_bib97) 1995; 52 Woolley (10.1016/j.neuropharm.2011.06.007_bib124) 2008; 196 Homayoun (10.1016/j.neuropharm.2011.06.007_bib62) 2006; 16 Harich (10.1016/j.neuropharm.2011.06.007_bib58) 2007; 192 Law (10.1016/j.neuropharm.2011.06.007_bib74) 2001; 12 Tsai (10.1016/j.neuropharm.2011.06.007_bib121) 2002; 42 Niswender (10.1016/j.neuropharm.2011.06.007_bib94) 2010; 50 Javitt (10.1016/j.neuropharm.2011.06.007_bib64) 1991; 148 Corti (10.1016/j.neuropharm.2011.06.007_bib26) 2007; 62 Gonzalez-Maeso (10.1016/j.neuropharm.2011.06.007_bib49) 2008; 452 Gozzi (10.1016/j.neuropharm.2011.06.007_bib50) 2008; 33 Kim (10.1016/j.neuropharm.2011.06.007_bib67) 1980; 20 Seeman (10.1016/j.neuropharm.2011.06.007_bib114) 2008; 62 Bromet (10.1016/j.neuropharm.2011.06.007_bib13) 1999; 46 Greco (10.1016/j.neuropharm.2011.06.007_bib51) 2005; 179 Nakazato (10.1016/j.neuropharm.2011.06.007_bib91) 2000; 43 Zeng (10.1016/j.neuropharm.2011.06.007_bib126) 1997; 321 Aultman (10.1016/j.neuropharm.2011.06.007_bib8) 2001; 153 Rorick-Kehn (10.1016/j.neuropharm.2011.06.007_bib105) 2007; 193 Cherlyn (10.1016/j.neuropharm.2011.06.007_bib23) 2010; 34 Aghajanian (10.1016/j.neuropharm.2011.06.007_bib1) 1997; 36 Pehrson (10.1016/j.neuropharm.2011.06.007_bib101) 2010; 211 Weinberger (10.1016/j.neuropharm.2011.06.007_bib123) 2007; 13 Coyle (10.1016/j.neuropharm.2011.06.007_bib27) 2006; 26 Zysk (10.1016/j.neuropharm.2011.06.007_bib128) 2010 Gu (10.1016/j.neuropharm.2011.06.007_bib54) 2008; 1197 Rorick-Kehn (10.1016/j.neuropharm.2011.06.007_bib104) 2007; 321 Marek (10.1016/j.neuropharm.2011.06.007_bib80) 2008; 55 Lahti (10.1016/j.neuropharm.2011.06.007_bib73) 1999; 22 Schoepp (10.1016/j.neuropharm.2011.06.007_bib110) 2001; 299 Dedeurwaerdere (10.1016/j.neuropharm.2011.06.007_bib30) 2010; 214 Hackler (10.1016/j.neuropharm.2011.06.007_bib56) 2010; 168 Holcomb (10.1016/j.neuropharm.2011.06.007_bib60) 2005; 30 Krystal (10.1016/j.neuropharm.2011.06.007_bib72) 1994; 51 Moghaddam (10.1016/j.neuropharm.2011.06.007_bib86) 1998; 281 Gao (10.1016/j.neuropharm.2011.06.007_bib45) 2000; 157 Fell (10.1016/j.neuropharm.2011.06.007_bib37) 2008; 326 Duncan (10.1016/j.neuropharm.2011.06.007_bib33) 1999; 843 Klodzinska (10.1016/j.neuropharm.2011.06.007_bib69) 2002; 73 Bishop (10.1016/j.neuropharm.2011.06.007_bib10) 2005; 77 Marek (10.1016/j.neuropharm.2011.06.007_bib81) 2000; 292 Corti (10.1016/j.neuropharm.2011.06.007_bib25) 2007; 27 Lorrain (10.1016/j.neuropharm.2011.06.007_bib76) 2003; 117 Gupta (10.1016/j.neuropharm.2011.06.007_bib55) 2005; 57 Chen (10.1016/j.neuropharm.2011.06.007_bib22) 2005; 73 Schaffhauser (10.1016/j.neuropharm.2011.06.007_bib108) 2003; 64 Andreasen (10.1016/j.neuropharm.2011.06.007_bib5) 1993; 19 Fraley (10.1016/j.neuropharm.2011.06.007_bib40) 2009; 19 Aronica (10.1016/j.neuropharm.2011.06.007_bib6) 2003; 17 Grillon (10.1016/j.neuropharm.2011.06.007_bib52) 2003; 168 Marek (10.1016/j.neuropharm.2011.06.007_bib79) 2010; 639 Ghose (10.1016/j.neuropharm.2011.06.007_bib48) 2009; 111 Seeman (10.1016/j.neuropharm.2011.06.007_bib115) 2009; 63 Lisman (10.1016/j.neuropharm.2011.06.007_bib75) 2008; 31 Auclair (10.1016/j.neuropharm.2011.06.007_bib7) 2002; 22 Cartmell (10.1016/j.neuropharm.2011.06.007_bib18) 2000; 400 Petralia (10.1016/j.neuropharm.2011.06.007_bib102) 1996; 71 Bruno (10.1016/j.neuropharm.2011.06.007_bib14) 2001; 21 Galici (10.1016/j.neuropharm.2011.06.007_bib44) 2006; 318 Higgins (10.1016/j.neuropharm.2011.06.007_bib59) 2004; 46 Patil (10.1016/j.neuropharm.2011.06.007_bib100) 2007; 13 Krystal (10.1016/j.neuropharm.2011.06.007_bib71) 1999; 22 Spooren (10.1016/j.neuropharm.2011.06.007_bib117) 2000; 397 Nikiforuk (10.1016/j.neuropharm.2011.06.007_bib93) 2010 Allison (10.1016/j.neuropharm.2011.06.007_bib4) 1999; 156 Kinon (10.1016/j.neuropharm.2011.06.007_bib68) 2010; 117 Monn (10.1016/j.neuropharm.2011.06.007_bib90) 1997; 40 Svensson (10.1016/j.neuropharm.2011.06.007_bib118) 2010; 117 Doumazane (10.1016/j.neuropharm.2011.06.007_bib31) 2011 Seeman (10.1016/j.neuropharm.2011.06.007_bib113) 2008; 99 Monn (10.1016/j.neuropharm.2011.06.007_bib89) 1999; 42 Fujii (10.1016/j.neuropharm.2011.06.007_bib42) 2003; 13 Monn (10.1016/j.neuropharm.2011.06.007_bib87) 2007; 50 Swanson (10.1016/j.neuropharm.2011.06.007_bib119) 2003; 1003 Fell (10.1016/j.neuropharm.2011.06.007_bib39) 2009; 331 Brnardic (10.1016/j.neuropharm.2011.06.007_bib12) 2010; 20 Cartmell (10.1016/j.neuropharm.2011.06.007_bib19) 2000; 75 Garbaccio (10.1016/j.neuropharm.2011.06.007_bib46) 2010; 1 Olney (10.1016/j.neuropharm.2011.06.007_bib98) 1999; 33 Roth (10.1016/j.neuropharm.2011.06.007_bib106) 1994; 268 Marino (10.1016/j.neuropharm.2011.06.007_bib82) 2002; 1 Wright (10.1016/j.neuropharm.2011.06.007_bib125) 2001; 298 Jones (10.1016/j.neuropharm.2011.06.007_bib66) 2010 Rowe (10.1016/j.neuropharm.2011.06.007_bib107) 2008; 326 Ohishi (10.1016/j.neuropharm.2011.06.007_bib95) 1993; 53 Pilowsky (10.1016/j.neuropharm.2011.06.007_bib103) 2006; 11 Schlumberger (10.1016/j.neuropharm.2011.06.007_bib109) 2009; 20 Schreiber (10.1016/j.neuropharm.2011.06.007_bib112) 2000; 388 Ohishi (10.1016/j.neuropharm.2011.06.007_bib96) 1993; 335 Dunayevich (10.1016/j.neuropharm.2011.06.007_bib32) 2008; 33 Parada-Turska (10.1016/j.neuropharm.2011.06.007_bib99) 1990; 29 Cartmell (10.1016/j.neuropharm.2011.06.007_bib20) 2001; 40 Cartmell (10.1016/j.neuropharm.2011.06.007_bib17) 2000; 148 Danysz (10.1016/j.neuropharm.2011.06.007_bib28) 1994; 48 Duncan (10.1016/j.neuropharm.2011.06.007_bib34) 1998; 787 Lorrain (10.1016/j.neuropharm.2011.06.007_bib77) 2005; 48 Michelson (10.1016/j.neuropharm.2011.06.007_bib83) 2005; 49 Johnson (10.1016/j.neuropharm.2011.06.007_bib65) 2005; 179 Miyamoto (10.1016/j.neuropharm.2011.06.007_bib84) 2005; 10 Egan (10.1016/j.neuropharm.2011.06.007_bib35) 2004; 101 Aghajanian (10.1016/j.neuropharm.2011.06.007_bib2) 1999; 21 Freedman (10.1016/j.neuropharm.2011.06.007_bib41) 2003; 349 Cartmell (10.1016/j.neuropharm.2011.06.007_bib21) 2000; 75 Nicoletti (10.1016/j.neuropharm.2011.06.007_bib92) 1996; 19 Zhai (10.1016/j.neuropharm.2011.06.007_bib127) 2003; 28 Schoepp (10.1016/j.neuropharm.2011.06.007_bib111) 1999; 38 Cartmell (10.1016/j.neuropharm.2011.06.007_bib16) 1999; 291 Monn (10.1016/j.neuropharm.2011.06.007_bib88) 1996; 39 Galici (10.1016/j.neuropharm.2011.06.007_bib43) 2005; 315 Boyle (10.1016/j.neuropharm.2011.06.007_bib11) 2003; 13 Akbarian (10.1016/j.neuropharm.2011.06.007_bib3) 1996; 16 Imre (10.1016/j.neuropharm.2011.06.007_bib63) 2007; 13 Danysz (10.1016/j.neuropharm.2011.06.007_bib29) 1988; 27 Gruber (10.1016/j.neuropharm.2011.06.007_bib53) 2010; 30 Krystal (10.1016/j.neuropharm.2011.06.007_bib70) 2005; 179 Homayoun (10.1016/j.neuropharm.2011.06.007_bib61) 2005; 93 Benneyworth (10.1016/j.neuropharm.2011.06.007_bib9) 2007; 72 Uslaner (10.1016/j.neuropharm.2011.06.007_bib122) 2009; 206 Bymaster (10.1016/j.neuropharm.2011.06.007_bib15) 1996; 14 Moghaddam (10.1016/j.neuropharm.2011.06.007_bib85) 1997; 17 Hahn (10.1016/j.neuropharm.2011.06.007_bib57) 2006; 12 Spinelli (10.1016/j.neuropharm.2011.06.007_bib116) 2005; 179 |
| References_xml | – volume: 101 start-page: 12604 year: 2004 end-page: 12609 ident: bib35 article-title: Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia publication-title: Proc. Natl. Acad. Sci. U.S.A. – volume: 1003 start-page: 309 year: 2003 end-page: 317 ident: bib119 article-title: A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists publication-title: Ann. N.Y. Acad. Sci. – volume: 52 start-page: 998 year: 1995 end-page: 1007 ident: bib97 article-title: Glutamate receptor dysfunction and schizophrenia publication-title: Arch. Gen. Psychiatry – volume: 400 start-page: 221 year: 2000 end-page: 224 ident: bib18 article-title: The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing publication-title: Eur. J. Pharmacol. – volume: 111 start-page: 131 year: 2009 end-page: 137 ident: bib48 article-title: Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia publication-title: Schizophr. Res. – volume: 1 start-page: 1 year: 2002 end-page: 16 ident: bib82 article-title: Direct and indirect modulation of the publication-title: Curr. Drug Targets CNS Neurol. Disord. – volume: 335 start-page: 252 year: 1993 end-page: 266 ident: bib96 article-title: Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study publication-title: J. Comp. Neurol. – volume: 28 start-page: 1622 year: 2003 end-page: 1632 ident: bib78 article-title: Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge publication-title: Neuropsychopharmacology – volume: 179 start-page: 303 year: 2005 end-page: 309 ident: bib70 article-title: Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects publication-title: Psychopharmacology (Berl.) – volume: 22 start-page: 9150 year: 2002 end-page: 9154 ident: bib7 article-title: D-amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release publication-title: J. Neurosci. – volume: 206 start-page: 641 year: 2009 end-page: 651 ident: bib122 article-title: Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants publication-title: Psychopharmacology (Berl.) – volume: 57 start-page: 1 year: 1993 end-page: 78 ident: bib36 article-title: Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs publication-title: Pharmacol. Ther. – volume: 30 start-page: 2275 year: 2005 end-page: 2282 ident: bib60 article-title: Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia publication-title: Neuropsychopharmacology – year: 2010 ident: bib93 article-title: Effects of a positive allosteric modulator of mGlu2 receptors LY487379 on cognitive flexibility and impulsive-like responding in rats publication-title: J. Pharmacol. Exp. Ther. – volume: 93 start-page: 1989 year: 2005 end-page: 2001 ident: bib61 article-title: Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats publication-title: J. Neurophysiol. – volume: 28 start-page: 45 year: 2003 end-page: 52 ident: bib127 article-title: Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex publication-title: Neuropsychopharmacology – volume: 27 start-page: 653 year: 1988 end-page: 656 ident: bib29 article-title: Learning impairment in rats by publication-title: Neuropharmacology – volume: 148 start-page: 423 year: 2000 end-page: 429 ident: bib17 article-title: Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine publication-title: Psychopharmacology (Berl.) – volume: 326 start-page: 209 year: 2008 end-page: 231 ident: bib37 article-title: Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039 publication-title: J. Pharmacol. Exp. Ther. – volume: 12 start-page: 2971 year: 2001 end-page: 2974 ident: bib74 article-title: Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses publication-title: Neuroreport – volume: 326 start-page: 240 year: 2008 end-page: 251 ident: bib107 article-title: Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site publication-title: J. Pharmacol. Exp. Ther. – volume: 22 year: 1999 ident: bib71 article-title: Therapeutic implications of the hyperglutamatergic effects of NMAD antagonists publication-title: Neuropsychopharmacology – volume: 77 start-page: 253 year: 2005 end-page: 260 ident: bib10 article-title: Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment publication-title: Schizophr. Res. – volume: 12 start-page: 824 year: 2006 end-page: 828 ident: bib57 article-title: Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia publication-title: Nat. Med. – start-page: 66 year: 2011 end-page: 77 ident: bib31 article-title: A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors publication-title: FASEB J – volume: 53 start-page: 1009 year: 1993 end-page: 1018 ident: bib95 article-title: Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat publication-title: Neuroscience – volume: 27 start-page: 8297 year: 2007 end-page: 8308 ident: bib25 article-title: The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection publication-title: J. Neurosci. – volume: 168 start-page: 209 year: 2010 end-page: 218 ident: bib56 article-title: Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation publication-title: Neuroscience – volume: 281 start-page: 1349 year: 1998 end-page: 1352 ident: bib86 article-title: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats publication-title: Science – volume: 148 start-page: 1301 year: 1991 end-page: 1308 ident: bib64 article-title: Recent advances in the phencyclidine model of schizophrenia publication-title: Am. J. Psychiatry – volume: 20 start-page: 56 year: 2009 end-page: 66 ident: bib109 article-title: Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition publication-title: Behav. Pharmacol. – volume: 397 start-page: R1 year: 2000 ident: bib117 article-title: Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice publication-title: Eur. J. Pharmacol. – volume: 21 start-page: 1013 year: 2001 end-page: 1033 ident: bib14 article-title: Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs publication-title: J. Cereb. Blood Flow Metab. – volume: 1197 start-page: 47 year: 2008 end-page: 62 ident: bib54 article-title: Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition publication-title: Brain Res. – volume: 321 start-page: 349 year: 1997 end-page: 354 ident: bib126 article-title: Muscarinic m4 receptor activation by some atypical antipsychotic drugs publication-title: Eur. J. Pharmacol. – volume: 75 start-page: 1147 year: 2000 end-page: 1154 ident: bib19 article-title: The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat publication-title: J. Neurochem. – volume: 71 start-page: 949 year: 1996 end-page: 976 ident: bib102 article-title: The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations publication-title: Neuroscience – volume: 298 start-page: 453 year: 2001 end-page: 460 ident: bib125 article-title: [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain publication-title: J. Pharmacol. Exp. Ther. – volume: 292 start-page: 76 year: 2000 end-page: 87 ident: bib81 article-title: Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex publication-title: J. Pharmacol. Exp. Ther. – volume: 40 start-page: 847 year: 2001 end-page: 855 ident: bib20 article-title: Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade publication-title: Neuropharmacology – volume: 73 start-page: 327 year: 2002 end-page: 332 ident: bib69 article-title: Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice publication-title: Pharmacol. Biochem. Behav. – volume: 639 start-page: 81 year: 2010 end-page: 90 ident: bib79 article-title: Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition publication-title: Eur. J. Pharmacol. – volume: 55 start-page: 608 year: 2008 ident: bib80 article-title: Activation of mGlu2 receptors mediates the “antipsychotic-like” activity of mGlu2/3 receptor agonists in three psychotomimetic drug models and regional distribution of mGlu2 vs mGlu3 receptors publication-title: Neuropharmacology – volume: 31 start-page: 234 year: 2008 end-page: 242 ident: bib75 article-title: Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia publication-title: Trends Neurosci. – volume: 33 start-page: 523 year: 1999 end-page: 533 ident: bib98 article-title: NMDA receptor hypofunction model of schizophrenia publication-title: J. Psychiatr. Res. – volume: 50 start-page: 233 year: 2007 end-page: 240 ident: bib87 article-title: Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (−)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors publication-title: J. Med. Chem. – volume: 13 start-page: S365 year: 2003 end-page: S375 ident: bib11 article-title: Evaluation of the cognitive and psychomotor profile of a novel anxiolytic, LY544344, compared to lorazepam in normal volunteers publication-title: Eur. Neuropsychopharmacol. – volume: 19 start-page: 1259 year: 2009 end-page: 1275 ident: bib40 article-title: Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia publication-title: Expert. Opin. Ther. Pat. – volume: 1 start-page: 406 year: 2010 end-page: 410 ident: bib46 article-title: Discovery of oxazolobenzimidazoles as positive allosteric modulators for the mGluR2 receptor publication-title: ACS Med. Chem. Lett. – volume: 19 start-page: 199 year: 1993 end-page: 214 ident: bib5 article-title: Diagnosis and classification of schizophrenia publication-title: Schizophr. Bull. – volume: 30 start-page: 17102 year: 2010 end-page: 17110 ident: bib53 article-title: More is less: a disinhibited prefrontal cortex impairs cognitive flexibility publication-title: J. Neurosci. – volume: 787 start-page: 181 year: 1998 end-page: 190 ident: bib34 article-title: Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia publication-title: Brain Res. – volume: 20 start-page: 379 year: 1980 end-page: 382 ident: bib67 article-title: Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia publication-title: Neurosci. Lett. – volume: 75 start-page: 889 year: 2000 end-page: 907 ident: bib21 article-title: Regulation of neurotransmitter release by metabotropic glutamate receptors publication-title: J. Neurochem. – volume: 331 start-page: 1126 year: 2009 end-page: 1136 ident: bib39 article-title: In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268) publication-title: J. Pharmacol. Exp. Ther. – volume: 13 start-page: 1102 year: 2007 end-page: 1107 ident: bib100 article-title: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial publication-title: Nat. Med. – volume: 196 start-page: 431 year: 2008 end-page: 440 ident: bib124 article-title: The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity publication-title: Psychopharmacology (Berl.) – volume: 21 start-page: 16S year: 1999 end-page: 23S ident: bib2 article-title: Serotonin and hallucinogens publication-title: Neuropsychopharmacology – volume: 46 start-page: 907 year: 2004 end-page: 917 ident: bib59 article-title: Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent publication-title: Neuropharmacology – volume: 34 start-page: 958 year: 2010 end-page: 977 ident: bib23 article-title: Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance publication-title: Neurosci. Biobehav. Rev. – volume: 36 start-page: 589 year: 1997 end-page: 599 ident: bib1 article-title: Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells publication-title: Neuropharmacology – volume: 48 start-page: 927 year: 2005 end-page: 935 ident: bib77 article-title: Comparison of the effects of diazepam, the CRF1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stress-evoked extracellular norepinephrine levels publication-title: Neuropharmacology – volume: 10 start-page: 79 year: 2005 end-page: 104 ident: bib84 article-title: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs publication-title: Mol. Psychiatry – volume: 57 start-page: 123 year: 2005 end-page: 131 ident: bib55 article-title: Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia publication-title: Synapse – volume: 157 start-page: 1141 year: 2000 end-page: 1149 ident: bib45 article-title: Ionotropic glutamate receptors and expression of publication-title: Am. J. Psychiatry – volume: 179 start-page: 68 year: 2005 end-page: 76 ident: bib51 article-title: Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2/3) receptor agonist LY379268 publication-title: Psychopharmacology (Berl.) – volume: 62 start-page: 154 year: 2008 end-page: 158 ident: bib114 article-title: Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268 publication-title: Synapse – volume: 39 start-page: 2990 year: 1996 end-page: 3000 ident: bib88 article-title: Synthesis of the four isomers of 4-aminopyrrolidine-2,4-dicarboxylate: identification of a potent, highly selective, and systemically-active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase publication-title: J. Med. Chem. – volume: 20 start-page: 3129 year: 2010 end-page: 3133 ident: bib12 article-title: 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: hit-to-lead efforts publication-title: Bioorg. Med. Chem. Lett. – volume: 23 start-page: 569 year: 2000 end-page: 576 ident: bib47 article-title: Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors publication-title: Neuropsychopharmacology – volume: 50 start-page: 295 year: 2010 end-page: 322 ident: bib94 article-title: Metabotropic glutamate receptors: physiology, pharmacology, and disease publication-title: Annu. Rev. Pharmacol. Toxicol. – volume: 11 start-page: 118 year: 2006 end-page: 119 ident: bib103 article-title: First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients publication-title: Mol. Psychiatry – volume: 268 start-page: 1403 year: 1994 end-page: 1410 ident: bib106 article-title: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors publication-title: J. Pharmacol. Exp. Ther. – volume: 349 start-page: 1738 year: 2003 end-page: 1749 ident: bib41 article-title: Schizophrenia publication-title: N. Engl. J. Med. – volume: 13 start-page: 71 year: 2003 end-page: 76 ident: bib42 article-title: Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia publication-title: Psychiatr. Genet. – volume: 51 start-page: 199 year: 1994 end-page: 214 ident: bib72 article-title: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses publication-title: Arch. Gen. Psychiatry – volume: 43 start-page: 4893 year: 2000 end-page: 4909 ident: bib91 article-title: Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists publication-title: J. Med. Chem. – volume: 192 start-page: 511 year: 2007 end-page: 519 ident: bib58 article-title: Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment publication-title: Psychopharmacology (Berl.) – volume: 38 start-page: 1431 year: 1999 end-page: 1476 ident: bib111 article-title: Pharmacological agents acting at subtypes of metabotropic glutamate receptors publication-title: Neuropharmacology – volume: 99 start-page: 373 year: 2008 end-page: 374 ident: bib113 article-title: Glutamate agonists for schizophrenia stimulate dopamine D2High receptors publication-title: Schizophr. Res. – volume: 321 start-page: 308 year: 2007 end-page: 317 ident: bib104 article-title: Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (−)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039) publication-title: J. Pharmacol. Exp. Ther. – volume: 42 start-page: 165 year: 2002 end-page: 179 ident: bib121 article-title: Glutamatergic mechanisms in schizophrenia publication-title: Annu. Rev. Pharmacol. Toxicol. – volume: 72 start-page: 477 year: 2007 end-page: 484 ident: bib9 article-title: A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis publication-title: Mol. Pharmacol. – volume: 46 start-page: 871 year: 1999 end-page: 881 ident: bib13 article-title: Epidemiology and natural history of schizophrenia publication-title: Biol. Psychiatry – volume: 452 start-page: 93 year: 2008 end-page: 97 ident: bib49 article-title: Identification of a serotonin/glutamate receptor complex implicated in psychosis publication-title: Nature – volume: 26 start-page: 365 year: 2006 end-page: 384 ident: bib27 article-title: Glutamate and schizophrenia: beyond the dopamine hypothesis publication-title: Cell Mol. Neurobiol. – volume: 16 start-page: 93 year: 2006 end-page: 105 ident: bib62 article-title: Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors publication-title: Cereb. Cortex – volume: 193 start-page: 121 year: 2007 end-page: 136 ident: bib105 article-title: In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders publication-title: Psychopharmacology (Berl.) – volume: 156 start-page: 1686 year: 1999 end-page: 1696 ident: bib4 article-title: Antipsychotic-induced weight gain: a comprehensive research synthesis publication-title: Am. J. Psychiatry – volume: 17 start-page: 2106 year: 2003 end-page: 2118 ident: bib6 article-title: Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins publication-title: Eur. J. Neurosci. – volume: 315 start-page: 1181 year: 2005 end-page: 1187 ident: bib43 article-title: A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity publication-title: J. Pharmacol. Exp. Ther. – volume: 64 start-page: 798 year: 2003 end-page: 810 ident: bib108 article-title: Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2 publication-title: Mol. Pharmacol. – volume: 117 start-page: 379 year: 2010 end-page: 389 ident: bib68 article-title: LY2140023 Monohydrate: an agonist at the mGlu2/3 receptor for the treatment of schizophrenia publication-title: Schizophr. Res. – volume: 117 start-page: 697 year: 2003 end-page: 706 ident: bib76 article-title: Effects of ketamine and publication-title: Neuroscience – volume: 16 start-page: 19 year: 1996 end-page: 30 ident: bib3 article-title: Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics publication-title: J. Neurosci. – volume: 291 start-page: 161 year: 1999 end-page: 170 ident: bib16 article-title: The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats publication-title: J. Pharmacol. Exp. Ther. – volume: 179 start-page: 292 year: 2005 end-page: 302 ident: bib116 article-title: Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys publication-title: Psychopharmacology (Berl.) – volume: 48 start-page: 111 year: 1994 end-page: 118 ident: bib28 article-title: Glutamate antagonists have different effects on spontaneous locomotor activity in rats publication-title: Pharmacol. Biochem. Behav. – volume: 63 start-page: 935 year: 2009 end-page: 939 ident: bib115 article-title: Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor publication-title: Synapse – year: 2010 ident: bib66 article-title: The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat publication-title: Psychopharmacology (Berl.) – volume: 388 start-page: R3 year: 2000 end-page: R4 ident: bib112 article-title: LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine publication-title: Eur. J. Pharmacol. – volume: 214 start-page: 505 year: 2010 end-page: 514 ident: bib30 article-title: Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist publication-title: Psychopharmacology (Berl) – volume: 299 start-page: 12 year: 2001 end-page: 20 ident: bib110 article-title: Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system publication-title: J. Pharmacol. Exp. Ther. – volume: 62 start-page: 747 year: 2007 end-page: 755 ident: bib26 article-title: Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia publication-title: Biol. Psychiatry – volume: 29 start-page: 1111 year: 1990 end-page: 1116 ident: bib99 article-title: Excitatory amino acid antagonists and memory: effect of drugs acting at publication-title: Neuropharmacology – volume: 14 start-page: 87 year: 1996 end-page: 96 ident: bib15 article-title: Radioreceptor binding profile of the atypical antipsychotic olanzapine publication-title: Neuropsychopharmacology – volume: 211 start-page: 443 year: 2010 end-page: 455 ident: bib101 article-title: Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion publication-title: Psychopharmacology (Berl.) – volume: 179 start-page: 271 year: 2005 end-page: 283 ident: bib65 article-title: Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s) publication-title: Psychopharmacology (Berl.) – volume: 40 start-page: 528 year: 1997 end-page: 537 ident: bib90 article-title: Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties publication-title: J. Med. Chem. – volume: 153 start-page: 353 year: 2001 end-page: 364 ident: bib8 article-title: Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task publication-title: Psychopharmacology (Berl.) – volume: 168 start-page: 446 year: 2003 end-page: 454 ident: bib52 article-title: Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans publication-title: Psychopharmacology (Berl.) – volume: 19 start-page: 267 year: 1996 end-page: 271 ident: bib92 article-title: Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? publication-title: Trends Neurosci. – volume: 13 start-page: 444 year: 2007 end-page: 464 ident: bib63 article-title: The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268 publication-title: CNS Drug Rev. – volume: 49 start-page: 257 year: 2005 ident: bib83 article-title: Clinical studies with mGluR2/3 agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Proceedings and abstracts of the 5th international meeting on metabotropic glutamate receptors publication-title: Neuropharmacology – volume: 42 start-page: 1027 year: 1999 end-page: 1040 ident: bib89 article-title: Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors publication-title: J. Med. Chem. – year: 2010 ident: bib128 article-title: Absence of direct effects on the dopamine D2 receptor by mGluR2/3-selective receptor agonists LY 354,740 and LY 379,268 publication-title: Synapse – volume: 37 start-page: 205 year: 1997 end-page: 237 ident: bib24 article-title: Pharmacology and functions of metabotropic glutamate receptors publication-title: Annu. Rev. Pharmacol. Toxicol. – volume: 843 start-page: 171 year: 1999 end-page: 183 ident: bib33 article-title: Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine publication-title: Brain Res. – volume: 318 start-page: 173 year: 2006 end-page: 185 ident: bib44 article-title: Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice publication-title: J. Pharmacol. Exp. Ther. – volume: 33 start-page: 1603 year: 2008 end-page: 1610 ident: bib32 article-title: Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder publication-title: Neuropsychopharmacology – volume: 73 start-page: 21 year: 2005 end-page: 26 ident: bib22 article-title: A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population publication-title: Schizophr. Res. – volume: 33 start-page: 1690 year: 2008 end-page: 1703 ident: bib50 article-title: Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine publication-title: Neuropsychopharmacology – volume: 13 start-page: 1018 year: 2007 end-page: 1019 ident: bib123 article-title: Schizophrenia drug says goodbye to dopamine publication-title: Nat. Med. – volume: 117 start-page: 114 year: 2010 ident: bib118 article-title: The mGlu2 Receptor as a novel drug target publication-title: Schizophr. Res. – volume: 22 start-page: S158 year: 1999 end-page: S169 ident: bib73 article-title: NMDA-sensitive glutamate antagonism: a human model of psychosis publication-title: Neuropsychopharmacology – volume: 58 start-page: 632 year: 2010 end-page: 639 ident: bib38 article-title: Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge publication-title: Neuropharmacology – volume: 17 start-page: 2921 year: 1997 end-page: 2927 ident: bib85 article-title: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex publication-title: J. Neurosci. – volume: 15 start-page: 3896 year: 1995 end-page: 3904 ident: bib120 article-title: Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: modulation by metabotropic glutamate receptors publication-title: J. Neurosci. – volume: 117 start-page: 697 year: 2003 ident: 10.1016/j.neuropharm.2011.06.007_bib76 article-title: Effects of ketamine and N-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 publication-title: Neuroscience doi: 10.1016/S0306-4522(02)00652-8 – volume: 1197 start-page: 47 year: 2008 ident: 10.1016/j.neuropharm.2011.06.007_bib54 article-title: Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition publication-title: Brain Res. doi: 10.1016/j.brainres.2007.12.057 – volume: 17 start-page: 2106 year: 2003 ident: 10.1016/j.neuropharm.2011.06.007_bib6 article-title: Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins publication-title: Eur. J. Neurosci. doi: 10.1046/j.1460-9568.2003.02657.x – volume: 13 start-page: 71 year: 2003 ident: 10.1016/j.neuropharm.2011.06.007_bib42 article-title: Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia publication-title: Psychiatr. Genet. doi: 10.1097/01.ypg.0000056682.82896.b0 – volume: 22 start-page: S158 year: 1999 ident: 10.1016/j.neuropharm.2011.06.007_bib73 article-title: NMDA-sensitive glutamate antagonism: a human model of psychosis publication-title: Neuropsychopharmacology doi: 10.1016/S0893-133X(99)00132-3 – volume: 299 start-page: 12 year: 2001 ident: 10.1016/j.neuropharm.2011.06.007_bib110 article-title: Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system publication-title: J. Pharmacol. Exp. Ther. doi: 10.1016/S0022-3565(24)29296-X – volume: 388 start-page: R3 year: 2000 ident: 10.1016/j.neuropharm.2011.06.007_bib112 article-title: LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine publication-title: Eur. J. Pharmacol. doi: 10.1016/S0014-2999(99)00844-4 – volume: 349 start-page: 1738 year: 2003 ident: 10.1016/j.neuropharm.2011.06.007_bib41 article-title: Schizophrenia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra035458 – volume: 23 start-page: 569 year: 2000 ident: 10.1016/j.neuropharm.2011.06.007_bib47 article-title: Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors publication-title: Neuropsychopharmacology doi: 10.1016/S0893-133X(00)00136-6 – volume: 331 start-page: 1126 year: 2009 ident: 10.1016/j.neuropharm.2011.06.007_bib39 publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.109.160598 – volume: 326 start-page: 240 year: 2008 ident: 10.1016/j.neuropharm.2011.06.007_bib107 article-title: Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.108.138271 – volume: 34 start-page: 958 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib23 article-title: Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance publication-title: Neurosci. Biobehav. Rev. doi: 10.1016/j.neubiorev.2010.01.002 – volume: 93 start-page: 1989 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib61 article-title: Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats publication-title: J. Neurophysiol. doi: 10.1152/jn.00875.2004 – volume: 19 start-page: 199 year: 1993 ident: 10.1016/j.neuropharm.2011.06.007_bib5 article-title: Diagnosis and classification of schizophrenia publication-title: Schizophr. Bull. doi: 10.1093/schbul/19.2.199 – volume: 64 start-page: 798 year: 2003 ident: 10.1016/j.neuropharm.2011.06.007_bib108 article-title: Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2 publication-title: Mol. Pharmacol. doi: 10.1124/mol.64.4.798 – volume: 62 start-page: 747 year: 2007 ident: 10.1016/j.neuropharm.2011.06.007_bib26 article-title: Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2006.12.005 – volume: 29 start-page: 1111 year: 1990 ident: 10.1016/j.neuropharm.2011.06.007_bib99 article-title: Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks publication-title: Neuropharmacology doi: 10.1016/0028-3908(90)90034-O – volume: 19 start-page: 267 year: 1996 ident: 10.1016/j.neuropharm.2011.06.007_bib92 article-title: Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? publication-title: Trends Neurosci. doi: 10.1016/S0166-2236(96)20019-0 – volume: 42 start-page: 165 year: 2002 ident: 10.1016/j.neuropharm.2011.06.007_bib121 article-title: Glutamatergic mechanisms in schizophrenia publication-title: Annu. Rev. Pharmacol. Toxicol. doi: 10.1146/annurev.pharmtox.42.082701.160735 – volume: 639 start-page: 81 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib79 article-title: Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2010.02.058 – volume: 39 start-page: 2990 year: 1996 ident: 10.1016/j.neuropharm.2011.06.007_bib88 article-title: Synthesis of the four isomers of 4-aminopyrrolidine-2,4-dicarboxylate: identification of a potent, highly selective, and systemically-active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase publication-title: J. Med. Chem. doi: 10.1021/jm9601765 – volume: 52 start-page: 998 year: 1995 ident: 10.1016/j.neuropharm.2011.06.007_bib97 article-title: Glutamate receptor dysfunction and schizophrenia publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.1995.03950240016004 – volume: 1003 start-page: 309 year: 2003 ident: 10.1016/j.neuropharm.2011.06.007_bib119 article-title: A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists publication-title: Ann. N.Y. Acad. Sci. doi: 10.1196/annals.1300.019 – volume: 53 start-page: 1009 year: 1993 ident: 10.1016/j.neuropharm.2011.06.007_bib95 article-title: Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat publication-title: Neuroscience doi: 10.1016/0306-4522(93)90485-X – volume: 75 start-page: 1147 year: 2000 ident: 10.1016/j.neuropharm.2011.06.007_bib19 article-title: The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat publication-title: J. Neurochem. doi: 10.1046/j.1471-4159.2000.0751147.x – volume: 156 start-page: 1686 year: 1999 ident: 10.1016/j.neuropharm.2011.06.007_bib4 article-title: Antipsychotic-induced weight gain: a comprehensive research synthesis publication-title: Am. J. Psychiatry doi: 10.1176/ajp.156.11.1686 – volume: 1 start-page: 406 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib46 article-title: Discovery of oxazolobenzimidazoles as positive allosteric modulators for the mGluR2 receptor publication-title: ACS Med. Chem. Lett. doi: 10.1021/ml100115a – volume: 318 start-page: 173 year: 2006 ident: 10.1016/j.neuropharm.2011.06.007_bib44 article-title: Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.106.102046 – start-page: 66 issue: 1 year: 2011 ident: 10.1016/j.neuropharm.2011.06.007_bib31 article-title: A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors publication-title: FASEB J doi: 10.1096/fj.10-163147 – volume: 179 start-page: 68 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib51 article-title: Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2/3) receptor agonist LY379268 publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-004-2127-9 – volume: 211 start-page: 443 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib101 article-title: Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-010-1914-8 – volume: 58 start-page: 632 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib38 article-title: Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2009.11.014 – volume: 452 start-page: 93 year: 2008 ident: 10.1016/j.neuropharm.2011.06.007_bib49 article-title: Identification of a serotonin/glutamate receptor complex implicated in psychosis publication-title: Nature doi: 10.1038/nature06612 – volume: 28 start-page: 1622 year: 2003 ident: 10.1016/j.neuropharm.2011.06.007_bib78 article-title: Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300238 – volume: 168 start-page: 446 year: 2003 ident: 10.1016/j.neuropharm.2011.06.007_bib52 article-title: Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-003-1444-8 – volume: 19 start-page: 1259 year: 2009 ident: 10.1016/j.neuropharm.2011.06.007_bib40 article-title: Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia publication-title: Expert. Opin. Ther. Pat. doi: 10.1517/13543770903045009 – volume: 397 start-page: R1 year: 2000 ident: 10.1016/j.neuropharm.2011.06.007_bib117 article-title: Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice publication-title: Eur. J. Pharmacol. doi: 10.1016/S0014-2999(00)00269-7 – volume: 117 start-page: 114 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib118 article-title: The mGlu2 Receptor as a novel drug target publication-title: Schizophr. Res. doi: 10.1016/j.schres.2010.02.037 – volume: 179 start-page: 303 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib70 article-title: Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-004-1982-8 – volume: 168 start-page: 209 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib56 article-title: Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation publication-title: Neuroscience doi: 10.1016/j.neuroscience.2010.02.057 – volume: 99 start-page: 373 year: 2008 ident: 10.1016/j.neuropharm.2011.06.007_bib113 article-title: Glutamate agonists for schizophrenia stimulate dopamine D2High receptors publication-title: Schizophr. Res. doi: 10.1016/j.schres.2007.11.007 – year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib66 article-title: The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat publication-title: Psychopharmacology (Berl.) – volume: 77 start-page: 253 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib10 article-title: Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment publication-title: Schizophr. Res. doi: 10.1016/j.schres.2005.04.001 – volume: 315 start-page: 1181 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib43 article-title: A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.105.091074 – volume: 111 start-page: 131 year: 2009 ident: 10.1016/j.neuropharm.2011.06.007_bib48 article-title: Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia publication-title: Schizophr. Res. doi: 10.1016/j.schres.2009.03.038 – volume: 16 start-page: 93 year: 2006 ident: 10.1016/j.neuropharm.2011.06.007_bib62 article-title: Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors publication-title: Cereb. Cortex doi: 10.1093/cercor/bhi087 – volume: 268 start-page: 1403 year: 1994 ident: 10.1016/j.neuropharm.2011.06.007_bib106 article-title: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors publication-title: J. Pharmacol. Exp. Ther. doi: 10.1016/S0022-3565(25)38596-4 – volume: 48 start-page: 111 year: 1994 ident: 10.1016/j.neuropharm.2011.06.007_bib28 article-title: Glutamate antagonists have different effects on spontaneous locomotor activity in rats publication-title: Pharmacol. Biochem. Behav. doi: 10.1016/0091-3057(94)90506-1 – volume: 63 start-page: 935 year: 2009 ident: 10.1016/j.neuropharm.2011.06.007_bib115 article-title: Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor publication-title: Synapse doi: 10.1002/syn.20704 – volume: 335 start-page: 252 year: 1993 ident: 10.1016/j.neuropharm.2011.06.007_bib96 article-title: Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study publication-title: J. Comp. Neurol. doi: 10.1002/cne.903350209 – volume: 50 start-page: 295 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib94 article-title: Metabotropic glutamate receptors: physiology, pharmacology, and disease publication-title: Annu. Rev. Pharmacol. Toxicol. doi: 10.1146/annurev.pharmtox.011008.145533 – volume: 153 start-page: 353 year: 2001 ident: 10.1016/j.neuropharm.2011.06.007_bib8 article-title: Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task publication-title: Psychopharmacology (Berl.) doi: 10.1007/s002130000590 – volume: 31 start-page: 234 year: 2008 ident: 10.1016/j.neuropharm.2011.06.007_bib75 article-title: Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia publication-title: Trends Neurosci. doi: 10.1016/j.tins.2008.02.005 – volume: 73 start-page: 21 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib22 article-title: A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population publication-title: Schizophr. Res. doi: 10.1016/j.schres.2004.07.002 – volume: 321 start-page: 349 year: 1997 ident: 10.1016/j.neuropharm.2011.06.007_bib126 article-title: Muscarinic m4 receptor activation by some atypical antipsychotic drugs publication-title: Eur. J. Pharmacol. doi: 10.1016/S0014-2999(96)00956-9 – volume: 27 start-page: 8297 year: 2007 ident: 10.1016/j.neuropharm.2011.06.007_bib25 article-title: The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.1889-07.2007 – volume: 26 start-page: 365 year: 2006 ident: 10.1016/j.neuropharm.2011.06.007_bib27 article-title: Glutamate and schizophrenia: beyond the dopamine hypothesis publication-title: Cell Mol. Neurobiol. doi: 10.1007/s10571-006-9062-8 – volume: 326 start-page: 209 year: 2008 ident: 10.1016/j.neuropharm.2011.06.007_bib37 article-title: Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039 publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.108.136861 – volume: 206 start-page: 641 year: 2009 ident: 10.1016/j.neuropharm.2011.06.007_bib122 article-title: Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-009-1644-y – volume: 38 start-page: 1431 year: 1999 ident: 10.1016/j.neuropharm.2011.06.007_bib111 article-title: Pharmacological agents acting at subtypes of metabotropic glutamate receptors publication-title: Neuropharmacology doi: 10.1016/S0028-3908(99)00092-1 – volume: 49 start-page: 257 issue: Suppl. 1 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib83 article-title: Clinical studies with mGluR2/3 agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Proceedings and abstracts of the 5th international meeting on metabotropic glutamate receptors publication-title: Neuropharmacology – volume: 20 start-page: 379 year: 1980 ident: 10.1016/j.neuropharm.2011.06.007_bib67 article-title: Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia publication-title: Neurosci. Lett. doi: 10.1016/0304-3940(80)90178-0 – volume: 117 start-page: 379 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib68 article-title: LY2140023 Monohydrate: an agonist at the mGlu2/3 receptor for the treatment of schizophrenia publication-title: Schizophr. Res. doi: 10.1016/j.schres.2010.02.679 – volume: 400 start-page: 221 year: 2000 ident: 10.1016/j.neuropharm.2011.06.007_bib18 article-title: The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing publication-title: Eur. J. Pharmacol. doi: 10.1016/S0014-2999(00)00423-4 – volume: 27 start-page: 653 year: 1988 ident: 10.1016/j.neuropharm.2011.06.007_bib29 article-title: Learning impairment in rats by N-methyl-d-aspartate receptor antagonists publication-title: Neuropharmacology doi: 10.1016/0028-3908(88)90189-X – volume: 10 start-page: 79 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib84 article-title: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs publication-title: Mol. Psychiatry doi: 10.1038/sj.mp.4001556 – volume: 33 start-page: 523 year: 1999 ident: 10.1016/j.neuropharm.2011.06.007_bib98 article-title: NMDA receptor hypofunction model of schizophrenia publication-title: J. Psychiatr. Res. doi: 10.1016/S0022-3956(99)00029-1 – volume: 196 start-page: 431 year: 2008 ident: 10.1016/j.neuropharm.2011.06.007_bib124 article-title: The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-007-0974-x – volume: 33 start-page: 1603 year: 2008 ident: 10.1016/j.neuropharm.2011.06.007_bib32 article-title: Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1301531 – volume: 71 start-page: 949 year: 1996 ident: 10.1016/j.neuropharm.2011.06.007_bib102 article-title: The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations publication-title: Neuroscience doi: 10.1016/0306-4522(95)00533-1 – volume: 42 start-page: 1027 year: 1999 ident: 10.1016/j.neuropharm.2011.06.007_bib89 publication-title: J. Med. Chem. doi: 10.1021/jm980616n – volume: 28 start-page: 45 year: 2003 ident: 10.1016/j.neuropharm.2011.06.007_bib127 article-title: Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300013 – volume: 51 start-page: 199 year: 1994 ident: 10.1016/j.neuropharm.2011.06.007_bib72 article-title: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.1994.03950030035004 – volume: 22 year: 1999 ident: 10.1016/j.neuropharm.2011.06.007_bib71 article-title: Therapeutic implications of the hyperglutamatergic effects of NMAD antagonists publication-title: Neuropsychopharmacology – volume: 787 start-page: 181 year: 1998 ident: 10.1016/j.neuropharm.2011.06.007_bib34 article-title: Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia publication-title: Brain Res. doi: 10.1016/S0006-8993(97)01390-5 – volume: 30 start-page: 17102 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib53 article-title: More is less: a disinhibited prefrontal cortex impairs cognitive flexibility publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.4623-10.2010 – volume: 57 start-page: 123 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib55 article-title: Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia publication-title: Synapse doi: 10.1002/syn.20164 – volume: 50 start-page: 233 year: 2007 ident: 10.1016/j.neuropharm.2011.06.007_bib87 article-title: Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (−)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors publication-title: J. Med. Chem. doi: 10.1021/jm060917u – volume: 13 start-page: 444 year: 2007 ident: 10.1016/j.neuropharm.2011.06.007_bib63 article-title: The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268 publication-title: CNS Drug Rev. doi: 10.1111/j.1527-3458.2007.00024.x – volume: 179 start-page: 271 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib65 article-title: Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s) publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-004-2099-9 – volume: 37 start-page: 205 year: 1997 ident: 10.1016/j.neuropharm.2011.06.007_bib24 article-title: Pharmacology and functions of metabotropic glutamate receptors publication-title: Annu. Rev. Pharmacol. Toxicol. doi: 10.1146/annurev.pharmtox.37.1.205 – volume: 13 start-page: 1102 year: 2007 ident: 10.1016/j.neuropharm.2011.06.007_bib100 article-title: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial publication-title: Nat. Med. doi: 10.1038/nm1632 – volume: 15 start-page: 3896 year: 1995 ident: 10.1016/j.neuropharm.2011.06.007_bib120 article-title: Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: modulation by metabotropic glutamate receptors publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.15-05-03896.1995 – year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib128 article-title: Absence of direct effects on the dopamine D2 receptor by mGluR2/3-selective receptor agonists LY 354,740 and LY 379,268 publication-title: Synapse – volume: 36 start-page: 589 year: 1997 ident: 10.1016/j.neuropharm.2011.06.007_bib1 article-title: Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells publication-title: Neuropharmacology doi: 10.1016/S0028-3908(97)00051-8 – volume: 11 start-page: 118 year: 2006 ident: 10.1016/j.neuropharm.2011.06.007_bib103 article-title: First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients publication-title: Mol. Psychiatry doi: 10.1038/sj.mp.4001751 – volume: 62 start-page: 154 year: 2008 ident: 10.1016/j.neuropharm.2011.06.007_bib114 article-title: Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268 publication-title: Synapse doi: 10.1002/syn.20482 – volume: 20 start-page: 3129 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib12 article-title: 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: hit-to-lead efforts publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2010.03.089 – volume: 73 start-page: 327 year: 2002 ident: 10.1016/j.neuropharm.2011.06.007_bib69 article-title: Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice publication-title: Pharmacol. Biochem. Behav. doi: 10.1016/S0091-3057(02)00845-6 – volume: 46 start-page: 871 year: 1999 ident: 10.1016/j.neuropharm.2011.06.007_bib13 article-title: Epidemiology and natural history of schizophrenia publication-title: Biol. Psychiatry doi: 10.1016/S0006-3223(99)00153-5 – volume: 13 start-page: 1018 year: 2007 ident: 10.1016/j.neuropharm.2011.06.007_bib123 article-title: Schizophrenia drug says goodbye to dopamine publication-title: Nat. Med. doi: 10.1038/nm0907-1018 – volume: 292 start-page: 76 year: 2000 ident: 10.1016/j.neuropharm.2011.06.007_bib81 article-title: Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex publication-title: J. Pharmacol. Exp. Ther. doi: 10.1016/S0022-3565(24)35262-0 – volume: 43 start-page: 4893 year: 2000 ident: 10.1016/j.neuropharm.2011.06.007_bib91 article-title: Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists publication-title: J. Med. Chem. doi: 10.1021/jm000346k – volume: 14 start-page: 87 year: 1996 ident: 10.1016/j.neuropharm.2011.06.007_bib15 article-title: Radioreceptor binding profile of the atypical antipsychotic olanzapine publication-title: Neuropsychopharmacology doi: 10.1016/0893-133X(94)00129-N – year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib93 article-title: Effects of a positive allosteric modulator of mGlu2 receptors LY487379 on cognitive flexibility and impulsive-like responding in rats publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.110.170506 – volume: 46 start-page: 907 year: 2004 ident: 10.1016/j.neuropharm.2011.06.007_bib59 article-title: Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2004.01.018 – volume: 40 start-page: 528 year: 1997 ident: 10.1016/j.neuropharm.2011.06.007_bib90 publication-title: J. Med. Chem. doi: 10.1021/jm9606756 – volume: 12 start-page: 2971 year: 2001 ident: 10.1016/j.neuropharm.2011.06.007_bib74 article-title: Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses publication-title: Neuroreport doi: 10.1097/00001756-200109170-00043 – volume: 101 start-page: 12604 year: 2004 ident: 10.1016/j.neuropharm.2011.06.007_bib35 article-title: Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.0405077101 – volume: 55 start-page: 608 year: 2008 ident: 10.1016/j.neuropharm.2011.06.007_bib80 article-title: Activation of mGlu2 receptors mediates the “antipsychotic-like” activity of mGlu2/3 receptor agonists in three psychotomimetic drug models and regional distribution of mGlu2 vs mGlu3 receptors publication-title: Neuropharmacology – volume: 33 start-page: 1690 year: 2008 ident: 10.1016/j.neuropharm.2011.06.007_bib50 article-title: Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1301547 – volume: 48 start-page: 927 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib77 article-title: Comparison of the effects of diazepam, the CRF1 antagonist CP-154,526 and the group II mGlu receptor agonist LY379268 on stress-evoked extracellular norepinephrine levels publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2004.12.022 – volume: 193 start-page: 121 year: 2007 ident: 10.1016/j.neuropharm.2011.06.007_bib105 article-title: In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-007-0758-3 – volume: 843 start-page: 171 year: 1999 ident: 10.1016/j.neuropharm.2011.06.007_bib33 article-title: Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine publication-title: Brain Res. doi: 10.1016/S0006-8993(99)01776-X – volume: 321 start-page: 308 year: 2007 ident: 10.1016/j.neuropharm.2011.06.007_bib104 publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.106.110809 – volume: 281 start-page: 1349 year: 1998 ident: 10.1016/j.neuropharm.2011.06.007_bib86 article-title: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats publication-title: Science doi: 10.1126/science.281.5381.1349 – volume: 179 start-page: 292 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib116 article-title: Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-004-2126-x – volume: 40 start-page: 847 year: 2001 ident: 10.1016/j.neuropharm.2011.06.007_bib20 article-title: Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade publication-title: Neuropharmacology doi: 10.1016/S0028-3908(01)00034-X – volume: 22 start-page: 9150 year: 2002 ident: 10.1016/j.neuropharm.2011.06.007_bib7 article-title: D-amphetamine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.22-21-09150.2002 – volume: 214 start-page: 505 year: 2010 ident: 10.1016/j.neuropharm.2011.06.007_bib30 article-title: Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-010-2052-z – volume: 57 start-page: 1 year: 1993 ident: 10.1016/j.neuropharm.2011.06.007_bib36 article-title: Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs publication-title: Pharmacol. Ther. doi: 10.1016/0163-7258(93)90036-D – volume: 291 start-page: 161 year: 1999 ident: 10.1016/j.neuropharm.2011.06.007_bib16 article-title: The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats publication-title: J. Pharmacol. Exp. Ther. doi: 10.1016/S0022-3565(24)35084-0 – volume: 192 start-page: 511 year: 2007 ident: 10.1016/j.neuropharm.2011.06.007_bib58 article-title: Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-007-0742-y – volume: 20 start-page: 56 year: 2009 ident: 10.1016/j.neuropharm.2011.06.007_bib109 article-title: Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition publication-title: Behav. Pharmacol. doi: 10.1097/FBP.0b013e3283242f57 – volume: 1 start-page: 1 year: 2002 ident: 10.1016/j.neuropharm.2011.06.007_bib82 article-title: Direct and indirect modulation of the N-methyl d-aspartate receptor publication-title: Curr. Drug Targets CNS Neurol. Disord. doi: 10.2174/1568007023339544 – volume: 13 start-page: S365 year: 2003 ident: 10.1016/j.neuropharm.2011.06.007_bib11 article-title: Evaluation of the cognitive and psychomotor profile of a novel anxiolytic, LY544344, compared to lorazepam in normal volunteers publication-title: Eur. Neuropsychopharmacol. doi: 10.1016/S0924-977X(03)92148-1 – volume: 21 start-page: 16S year: 1999 ident: 10.1016/j.neuropharm.2011.06.007_bib2 article-title: Serotonin and hallucinogens publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1395318 – volume: 148 start-page: 423 year: 2000 ident: 10.1016/j.neuropharm.2011.06.007_bib17 article-title: Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine publication-title: Psychopharmacology (Berl.) doi: 10.1007/s002130050072 – volume: 21 start-page: 1013 year: 2001 ident: 10.1016/j.neuropharm.2011.06.007_bib14 article-title: Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs publication-title: J. Cereb. Blood Flow Metab. doi: 10.1097/00004647-200109000-00001 – volume: 12 start-page: 824 year: 2006 ident: 10.1016/j.neuropharm.2011.06.007_bib57 article-title: Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia publication-title: Nat. Med. doi: 10.1038/nm1418 – volume: 157 start-page: 1141 year: 2000 ident: 10.1016/j.neuropharm.2011.06.007_bib45 article-title: Ionotropic glutamate receptors and expression of N-methyl-d-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.157.7.1141 – volume: 72 start-page: 477 year: 2007 ident: 10.1016/j.neuropharm.2011.06.007_bib9 article-title: A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis publication-title: Mol. Pharmacol. doi: 10.1124/mol.107.035170 – volume: 30 start-page: 2275 year: 2005 ident: 10.1016/j.neuropharm.2011.06.007_bib60 article-title: Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300824 – volume: 148 start-page: 1301 year: 1991 ident: 10.1016/j.neuropharm.2011.06.007_bib64 article-title: Recent advances in the phencyclidine model of schizophrenia publication-title: Am. J. Psychiatry doi: 10.1176/ajp.148.10.1301 – volume: 16 start-page: 19 year: 1996 ident: 10.1016/j.neuropharm.2011.06.007_bib3 article-title: Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.16-01-00019.1996 – volume: 75 start-page: 889 year: 2000 ident: 10.1016/j.neuropharm.2011.06.007_bib21 article-title: Regulation of neurotransmitter release by metabotropic glutamate receptors publication-title: J. Neurochem. doi: 10.1046/j.1471-4159.2000.0750889.x – volume: 298 start-page: 453 year: 2001 ident: 10.1016/j.neuropharm.2011.06.007_bib125 article-title: [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain publication-title: J. Pharmacol. Exp. Ther. doi: 10.1016/S0022-3565(24)29402-7 – volume: 17 start-page: 2921 year: 1997 ident: 10.1016/j.neuropharm.2011.06.007_bib85 article-title: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.17-08-02921.1997 |
| SSID | ssj0004818 |
| Score | 2.3380766 |
| SecondaryResourceType | review_article |
| Snippet | Schizophrenia is a devastating chronic psychotic disorder characterized by positive, negative, and cognitive symptoms. Although the positive symptoms are... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1473 |
| SubjectTerms | Allosteric Regulation - drug effects Animals Excitatory Amino Acid Agonists - pharmacology Excitatory Amino Acid Agonists - therapeutic use Glutamate Humans LY2140023 mGlu2 positive allosteric modulator mGlu2/3 receptor agonist Receptors, Metabotropic Glutamate - agonists Receptors, Metabotropic Glutamate - physiology Schizophrenia Schizophrenia - drug therapy Schizophrenia - metabolism Signal Transduction - drug effects |
| Title | Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia |
| URI | https://dx.doi.org/10.1016/j.neuropharm.2011.06.007 https://www.ncbi.nlm.nih.gov/pubmed/21704048 https://www.proquest.com/docview/917576212 https://www.proquest.com/docview/923195768 |
| Volume | 62 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwELUQXLhUbaHtthTNAXEiBW_sdSxOCIF2qYo4gMTNij-CtoJkRQISPfDbmYmTXTiAkHpMZEsjz8TzJn7zzNgWdXuI3GJZ4kY-EZkVSS6LNEkRLWN2sN5yanD-czoaX4iTS3m5xA77XhiiVXZ7f9zT2926e7PbrebubDqlHl9MjRpTGo-yetTBLhRF-a_HBc1DZDzrlZhpdMfmiRyvVjNyRhrRnZgnnUyo11LUaxC0TUXHH9mHDkPCQTTzE1sK5We2fRZFqB924HzRU1XvwDacLeSpH9bYv_Z3E0wmcBMaDIEGbZs6uMIQzBG-BsD1CDMsxSG_qkhXt4a89BDZXfcB6KSe1BVwzk3l6fav6haH1FBW9-Ea5sz1GhAPQ_2c1LfOLo6Pzg_HSXcDQ-IwaTWJly7lwuVKWisRaDjOVVp4j37VUuXahcxaMZJe7zmPwYBoxgXuh1iu66B5SL-w5bIqwzcGSlkdvNTSuiDsSOoitZrTHXrDtCj2hgOm-kU3rpMnp1syrk3PQ_trFu4y5C7TUvLUgPH5zFmU6HjHnP3er-ZFuBnMJO-YDX0oGPwa6YglL0N1VxssfrGAQzjwxhBE1JqqvAH7GqNobjWWh7iniuz7f1n3g63i0zAS5TbYcnN7F34icmrsZvtpbLKVg8nv8ekTsjMevQ |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB3R5dBeUAtt2dKWOSBOROBNvInVE0JFu3ysOCwSNyv-CFoEyYoEJPrrGcfOLj1QIfWaZCTLHnvexG_eAOy4ao8kV5SW6KGJkkwlUc6LOIoJLVN0UEYxV-B8PhmOLpOTK361AkddLYyjVYaz35_p7WkdnuyH2dyfz2auxpdCo6CQxrys3jtYdepUvAerh-PT0WRZHpmxrBNjdgaB0ONpXq1s5NzJRAc9T3c5kb4WpV5DoW00Ov4IawFG4qEf6SdYseU67F54HeqnPZwuy6rqPdzFi6VC9dMG_Gn_OOF4jHe2IS9oaGwzjdfkhTkhWIs0JXZO2Tjm15WT1q0xLw16gtejRXdZ7wQWyOauMq4BWHVPn9RYVo_2Fhfk9RoJEmP9ktf3GS6Pf0-PRlFowhBpiltNZLiOWaLzlCvFCWtoxtK4MIaWVvA0F9pmSiVDbsSBNuQPBGi0ZWZAGbuwgtn4C_TKqrSbgGmqhDVccKVtooZcFLESzLXRG8RFcTDoQ9pNutRBodw1yriVHRXtRi6XS7rlki0rL-0DW1jOvUrHG2x-desq__I4ScHkDdbYuYKkDeluWfLSVg-1pPyXcjhCBP_4hEC1cIleH756L1qMmjJEOlaT7Nt_jW4b3o-m52fybDw53YIP9GbgeXPfodfcP9gfBKQa9TNslGdiSyFu |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Group+II+metabotropic+glutamate+receptor+agonists+and+positive+allosteric+modulators+as+novel+treatments+for+schizophrenia&rft.jtitle=Neuropharmacology&rft.au=Fell%2C+Matthew+J.&rft.au=McKinzie%2C+David+L.&rft.au=Monn%2C+James+A.&rft.au=Svensson%2C+Kjell+A.&rft.date=2012-03-01&rft.issn=0028-3908&rft.volume=62&rft.issue=3&rft.spage=1473&rft.epage=1483&rft_id=info:doi/10.1016%2Fj.neuropharm.2011.06.007&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_neuropharm_2011_06_007 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-3908&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-3908&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-3908&client=summon |